Venus Remedies Limited
NSE: VENUSREM BSE: VENUSREM
Prev Close
473.95
Open Price
483.4
Volume
24,425
Today Low / High
473.95 / 483.4
52 WK Low / High
270.25 / 567.8
Range
459 - 508
Prev Close
472.25
Open Price
481.65
Volume
7,636
Today Low / High
464.7 / 481.65
52 WK Low / High
272.2 / 565.95
Range
458 - 506
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 483.4 (target range: 459 - 508), reflecting a change of 9.45 (1.99388%). On the BSE, it is listed at 481.65 (target range: 458 - 506), showing a change of 9.4 (1.99047%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Venus Remedies Limited Graph
Venus Remedies Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Venus Remedies Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 483.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 481.65 | 486.47 | 437.82 - 535.11 |
491.28 | 393.03 - 589.54 | ||
496.10 | 347.27 - 644.93 | ||
Bearish Scenario | 481.65 | 476.83 | 429.15 - 524.52 |
472.02 | 377.61 - 566.42 | ||
467.20 | 327.04 - 607.36 |
Overview of Venus Remedies Limited
ISIN
INE411B01019
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
72,132
Market Cap
6,420,170,100
Last Dividend
0
Official Website
IPO Date
2006-12-20
DCF Diff
-655.81
DCF
1,136
Financial Ratios Every Investor Needs
Stock Dividend of VENUSREM
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2013-09-23 | September 23, 13 | 3 | 3 | 2013-09-24 | 2013-10-30 | 2013-05-20 |
2012-09-20 | September 20, 12 | 3 | 3 | 2012-09-22 | 2012-10-28 | 2012-06-21 |
2011-09-22 | September 22, 11 | 3 | 3 | 2011-09-24 | 2011-10-30 | 2011-07-26 |
2010-09-23 | September 23, 10 | 3 | 3 | 2010-09-24 | 2010-10-27 | 2010-07-31 |
2009-09-17 | September 17, 09 | 3 | 3 | 2009-09-19 | 2009-10-30 | 2009-08-21 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 647.89 Cr | 481.62 Cr | 166.27 Cr | 0.2566 | 18.08 Cr | 0.00 Cr | 41.03 Cr | 45.32 Cr | 33.90 | 94.41 Cr | 0.0700 |
2024-03-31 | 591.45 Cr | 373.19 Cr | 218.26 Cr | 0.3690 | 15.84 Cr | 12.77 Cr | 33.16 Cr | 28.49 Cr | 21.31 | 71.18 Cr | 0.0482 |
2023-03-31 | 555.51 Cr | 330.99 Cr | 224.52 Cr | 0.4042 | 22.89 Cr | 11.56 Cr | 28.39 Cr | 26.57 Cr | 19.87 | 60.51 Cr | 0.0478 |
2022-03-31 | 598.65 Cr | 398.24 Cr | 200.41 Cr | 0.3348 | 23.03 Cr | 9.11 Cr | 29.04 Cr | 40.72 Cr | 30.47 | 62.58 Cr | 0.0680 |
2021-03-31 | 548.12 Cr | 351.96 Cr | 196.17 Cr | 0.3579 | 11.87 Cr | 11.16 Cr | 31.51 Cr | 61.77 Cr | 50.04 | 54.56 Cr | 0.1127 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 80.10 Cr | 715.72 Cr | 154.77 Cr | 560.9500 Cr | 1.69 Cr | -78.41 Cr | 100.49 Cr | 151.09 Cr | 0.00 Cr | 0.00 Cr | 5.72 Cr | 136.2900 Cr |
2024-03-31 | 48.96 Cr | 626.82 Cr | 139.27 Cr | 487.5501 Cr | 41.33 Cr | -7.63 Cr | 121.69 Cr | 155.30 Cr | 0.00 Cr | 0.00 Cr | 0.02 Cr | 79.4158 Cr |
2023-03-31 | 21.21 Cr | 601.08 Cr | 140.74 Cr | 460.3400 Cr | 42.29 Cr | 21.08 Cr | 119.94 Cr | 162.82 Cr | 27.03 Cr | 47.53 Cr | -50.89 Cr | 82.5700 Cr |
2022-03-31 | 43.26 Cr | 579.82 Cr | 139.37 Cr | 440.4464 Cr | 42.85 Cr | -0.41 Cr | 125.64 Cr | 178.63 Cr | 33.12 Cr | 0.00 Cr | -5.43 Cr | 92.7385 Cr |
2021-03-31 | 28.88 Cr | 555.85 Cr | 155.57 Cr | 400.2837 Cr | 51.32 Cr | 22.44 Cr | 119.99 Cr | 190.82 Cr | 20.62 Cr | 54.49 Cr | 4.00 Cr | 97.4451 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 90.9200 Cr | -80.7900 Cr | -0.9500 Cr | 81.2900 Cr | 0.0000 Cr | 80.1000 Cr | -18.0800 Cr | 45.3200 Cr | -0.9500 Cr | 0.0000 Cr | 0.0000 Cr |
2024-03-31 | 37.2853 Cr | -7.2093 Cr | -1.0827 Cr | 27.8400 Cr | 27.7436 Cr | 48.9558 Cr | -9.3182 Cr | 28.4908 Cr | -0.9891 Cr | 0.0000 Cr | 0.0000 Cr |
2023-03-31 | 36.6200 Cr | -50.8300 Cr | -0.5700 Cr | 28.8020 Cr | -22.0500 Cr | 21.2100 Cr | -7.8180 Cr | 37.9300 Cr | -0.4495 Cr | 0.0000 Cr | 0.0000 Cr |
2022-03-31 | 41.0013 Cr | -16.6264 Cr | -9.4771 Cr | 27.2936 Cr | 14.3764 Cr | 43.2556 Cr | -13.7077 Cr | 36.4081 Cr | -9.0156 Cr | 0.0000 Cr | 0.0000 Cr |
2021-03-31 | 132.6144 Cr | 55.7162 Cr | -162.2426 Cr | 124.8867 Cr | 26.9368 Cr | 28.8792 Cr | -7.7277 Cr | 25.1115 Cr | -168.9746 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 194.97 Cr | 128.93 Cr | 66.04 Cr | 0.3387 | 24.29 Cr | 21.00 Cr | 15.71 | 35.76 Cr | 0.1077 |
2024-12-31 | 176.86 Cr | 110.20 Cr | 66.66 Cr | 0.3769 | 12.95 Cr | 19.60 Cr | 14.66 | 30.30 Cr | 0.1108 |
2024-09-30 | 167.45 Cr | 135.69 Cr | 31.76 Cr | 0.1897 | -1.48 Cr | 3.51 Cr | 2.63 | 15.50 Cr | 0.0210 |
2024-06-30 | 108.61 Cr | 81.82 Cr | 26.79 Cr | 0.2467 | 5.28 Cr | 1.22 Cr | 0.91 | 12.85 Cr | 0.0112 |
2024-03-31 | 195.16 Cr | 145.66 Cr | 49.50 Cr | 0.2536 | 13.56 Cr | 10.52 Cr | 7.86 | 23.39 Cr | 0.0539 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 80.10 Cr | 84.09 Cr | 164.19 Cr | 112.22 Cr | 100.49 Cr | 451.72 Cr | 151.09 Cr | 715.72 Cr | 154.77 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 134.19 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -494.21 Cr |
2024-09-30 | 78.43 Cr | 55.76 Cr | 134.89 Cr | 82.56 Cr | 120.01 Cr | 391.48 Cr | 149.58 Cr | 660.46 Cr | 166.25 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 87.19 Cr | 0.00 Cr | 0.00 Cr | 87.19 Cr | 0.00 Cr | 0.00 Cr | -487.55 Cr |
2024-03-31 | 68.10 Cr | 19.09 Cr | 87.19 Cr | 80.50 Cr | 121.69 Cr | 359.53 Cr | 154.40 Cr | 626.83 Cr | 139.28 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 19.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 3.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 1.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 10.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 6.85 Cr | 13.08 Cr | 0.00 Cr | 0.00 Cr | 13.08 Cr | 80.76 Cr | 67.68 Cr | 0.00 Cr | 13.08 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,640.90 | ₹3,936,978,552,000.00 | ₹1,313,620.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,100.50 | ₹1,619,493,634,500.00 | ₹394,932.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,617.80 | ₹1,224,426,321,000.00 | ₹287,405.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,253.40 | ₹1,043,245,022,805.00 | ₹1,191,889.00 |
Mankind Pharma Limited | MANKIND | ₹2,466.00 | ₹1,017,789,122,160.00 | ₹376,033.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.60 | ₹994,758,978,000.00 | ₹1,911,246.00 |
Lupin Limited | LUPIN | ₹1,989.80 | ₹908,835,180,600.00 | ₹875,748.00 |
Alkem Laboratories Limited | ALKEM | ₹5,388.50 | ₹644,276,002,500.00 | ₹899,623.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,078.20 | ₹626,220,716,400.00 | ₹444,368.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,029.30 | ₹572,670,489,300.00 | ₹466,363.00 |
Laurus Labs Limited | LAURUSLABS | ₹863.15 | ₹465,949,948,750.00 | ₹2,817,579.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹986.05 | ₹377,230,198,238.00 | ₹177,879.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,364.60 | ₹346,204,478,400.00 | ₹113,365.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,671.70 | ₹333,791,511,200.00 | ₹40,260.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,715.50 | ₹268,163,529,000.00 | ₹62,276.00 |
Piramal Enterprises Limited | PEL | ₹1,127.20 | ₹255,511,441,600.00 | ₹243,681.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,501.60 | ₹243,978,466,400.00 | ₹325,967.00 |
Eris Lifesciences Limited | ERIS | ₹1,674.80 | ₹228,119,483,600.00 | ₹42,022.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,416.50 | ₹210,412,500,000.00 | ₹34,705.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹941.00 | ₹184,965,783,000.00 | ₹25,900.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,077.50 | ₹171,625,277,500.00 | ₹132,577.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,018.00 | ₹167,019,638,200.00 | ₹23,483.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,156.90 | ₹163,949,635,730.00 | ₹164,102.00 |
NATCO Pharma Limited | NATCOPHARM | ₹904.25 | ₹161,960,217,500.00 | ₹516,819.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹460.35 | ₹111,701,165,400.00 | ₹778,530.00 |
Procter & Gamble Health Limited | PGHL | ₹6,182.50 | ₹102,625,790,500.00 | ₹13,202.00 |
Shilpa Medicare Limited | SHILPAMED | ₹906.20 | ₹88,618,113,580.00 | ₹114,891.00 |
Strides Pharma Science Limited | STAR | ₹867.30 | ₹79,941,382,710.00 | ₹568,013.00 |
FDC Limited | FDC | ₹483.20 | ₹78,669,792,000.00 | ₹76,497.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹790.45 | ₹71,642,135,379.00 | ₹1,229,147.00 |
Innova Captab Limited | INNOVACAP | ₹902.00 | ₹51,616,886,860.00 | ₹24,559.00 |
Suven Life Sciences Limited | SUVEN | ₹232.25 | ₹50,647,686,500.00 | ₹235,893.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹142.28 | ₹46,172,990,160.00 | ₹192,243.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹488.05 | ₹44,544,323,500.00 | ₹79,719.00 |
Sequent Scientific Limited | SEQUENT | ₹171.51 | ₹42,934,955,850.00 | ₹221,470.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹768.10 | ₹38,957,340,710.00 | ₹102,241.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,281.60 | ₹37,735,382,400.00 | ₹9,674.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹513.80 | ₹36,174,500,040.00 | ₹45,592.00 |
Gufic Biosciences Limited | GUFICBIO | ₹356.70 | ₹35,769,162,600.00 | ₹36,115.00 |
Hikal Limited | HIKAL | ₹255.65 | ₹31,521,900,650.00 | ₹589,191.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹605.30 | ₹29,147,010,900.00 | ₹54,573.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹93.23 | ₹27,365,522,210.00 | ₹1,598,864.00 |
Indoco Remedies Limited | INDOCO | ₹293.70 | ₹27,093,208,230.00 | ₹138,144.00 |
Alembic Limited | ALEMBICLTD | ₹105.19 | ₹27,010,898,475.00 | ₹451,825.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹47.31 | ₹25,923,703,740.00 | ₹3,167,804.00 |
Key Executives
Gender: Not Specified
Year Born: 1969
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born: 1977
Gender: male
Year Born: 1971
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1964
Gender: male
Year Born: 1993
Gender: male
Year Born:
FAQs about Venus Remedies Limited
The CEO is Ashutosh Jain.
The current price is ₹480.30.
The range is ₹270.25-567.8.
The market capitalization is ₹642.02 crores.
The P/E ratio is 14.17.
The company operates in the Healthcare sector.
Overview of Venus Remedies Limited (ISIN: INE411B01019) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹642.02 crores and an average daily volume of 72,132 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.